CTOs on the Move

RootPath Genomics

www.rootpath.com

 
RootPath, Inc. is a Cambridge, MA-based early-stage biotechnology company focusing on next-generation immuno- and cell-therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RootPath Genomics raised $11M on 01/05/2020

Similar Companies

Cellartis AB

Cellartis AB is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vestaron

Recent winner of the Green Chemistry award, Vestaron is leading a peptide-based revolution in crop protection. We are committed to providing growers with novel, effective chemistries that address proven targets. Our peptides overcome existing resistance issues while offering a desired safety profile for workers, beneficials and the environment. Initially, Vestaron is focused on a class of peptides that kills insect pests efficiently, but is safe for humans, birds, fish, pollinators and the environment. As part of this, the company has developed a proprietary platform for peptide optimization and fermentation-based peptide production that will allow development of a wide variety of biologic crop protection solutions. Vestaron is proud to bring you the Power of Peptides through the SPEAR® brand family - providing new technology with a unique mode of action in a biological solution equal to, and often better, than the synthetic options; creating the opportunity to incorporate a new IRAC Group 32 into rotation recommendations for resistance management.

northcoast medical

northcoast medical is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Impact Biomedicines

Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.

Oncology Plus

Oncology Plus is a Brandon, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.